Clinical Pharmacokinetics and Pharmacodynamics of Warfarin

SummaryThe simplest complete system accounting for the time-course of changes in the prothrombin time induced by warfarin requires the combination of 4 independent models: 1.A pharmacokinetic model for the absorption, distribution, and elimination of warfarin. Warfarin is essentially completely absorbed, reaching a maximum plasma concentration between 2 and 6 hours. It distributes into a small volume of distribution (10 L/70kg) and is eliminated by hepatic metabolism with a very small clearance (0.2 L/h/70kg). The elimination half-life is about 35 hours.2.A pharmacodynamic model for the effect of warfarin on the synthesis of clotting factors (prothrombin complex). Prothrombin complex synthesis is inhibited 50% at a warfarin concentration of about 1.5 mg/L. Warfarin concentrations associated with therapeutic anticoagulation are of similar magnitude.3.A physiological model for the synthesis and degradation of the prothrombin complex. The synthesis rate is about 5%/h/70kg and the elimination half-life estimated from changes in prothrombin time is approximately 17 hours. On average it will take 3 days for the anticoagulant effect of warfarin to reach a stable value when warfarin concentrations are constant.4.A model for the relationship between the activity of prothrombin complex and the prothrombin time. In general there is a hyperbolic relationship between these quantities. Its exact shape depends upon the method used for measuring the prothrombin time. Attempts to integrate these models into a single system have used essentially the same pharmacokinetic, physiological, and prothrombin activity models. Four distinct pharmacodynamic models have been proposed: linear, log-linear, power and Emax. One might be preferred on theoretical grounds (Emax) but its performance is not clearly different from the others.Empirical methods for warfarin dose prediction as well as those based on the combined pharmacokinetic-pharmacodynamic-physiological-prothrombin system have been proposed. Only one (which was also the first) [Sheiner 1969] has been adequately described and compared with the performance of an unaided physician. The programme compared favourably with decisions made by those physicians normally responsible for adjusting warfarin dose, but was not tested prospectively.A sizeable body of theoretical and experimental observations has contributed to our understanding of the warfarin dose-effect relationship. It remains to be demonstrated that any alternative method is superior to the traditional empirical approach to warfarin dose adjustment.

[1]  A. Quick HEMORRHAGIC DISEASES. , 1958, California and western medicine.

[2]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1941 .

[3]  J. Flynn Blood clotting and allied problems : transactions of the Fifth Conference February 16-17, 1948, New York , 1948 .

[4]  L. B. Page SYLLABUS OF LABORATORY EXAMINATIONS IN CLINICAL DIAGNOSIS , 1961 .

[5]  R A O'REILLY,et al.  STUDIES ON THE COUMARIN ANTICOAGULANT DRUGS: THE PHARMACODYNAMICS OF WARFARIN IN MAN. , 1963, The Journal of clinical investigation.

[6]  H. Johnson,et al.  The cardia in swallowing, eructation, and vomiting. , 1966, Lancet.

[7]  P M Aggeler,et al.  Studies on Coumarin Anticoagulant Drugs: Initiation of Warfarin Therapy Without a Loading Dose , 1968, Circulation.

[8]  L B Sheiner,et al.  Computer-aided long-term anticoagulation therapy. , 1969, Computers and biomedical research, an international journal.

[9]  G. Levy,et al.  Kinetics of pharmacologic effects in man: The anticoagulant action of warfarin , 1969, Clinical pharmacology and therapeutics.

[10]  Pleural effusions in nonbacterial pneumonias. , 1970 .

[11]  P. M. Aggeler,et al.  Determinants of the response to oral anticoagulant drugs in man. , 1970, Pharmacological reviews.

[12]  D. Deykin Warfarin therapy. 1. , 1970, The New England journal of medicine.

[13]  Udall Ja No-load" warfarin therapy. , 1970 .

[14]  E. Sellers,et al.  Drug interactions with coumarin anticoagulants. 2. , 1971, The New England journal of medicine.

[15]  E. Sellers,et al.  Drug Interactions with Coumarin Anticoagulants , 1971 .

[16]  O'Reilly Ra,et al.  Pharmacokinetics of warfarin following intravenous administration to man. , 1971 .

[17]  T. Theofanous,et al.  Multiple-dose kinetics of oral anticoagulants: methods of analysis and optimized dosing. , 1973, Journal of pharmaceutical sciences.

[18]  A. Breckenridge,et al.  Kinetics of warfarin absorption in man , 1973, Clinical pharmacology and therapeutics.

[19]  A. Breckenridge,et al.  Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man , 1974, Clinical pharmacology and therapeutics.

[20]  A. Breckenridge,et al.  Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone. , 1974, The Journal of clinical investigation.

[21]  P. Abbrecht,et al.  Lack of interaction between ibuprofen and warfarin. , 1975, Current therapeutic research, clinical and experimental.

[22]  G. Levy,et al.  Intrasubject variation of warfarin binding to protein in serum of patients with cardiovascular disease , 1976, Clinical pharmacology and therapeutics.

[23]  A M Vossepoel,et al.  A computer program for long term anticoagulation control. , 1977, Computer programs in biomedicine.

[24]  S. Husted,et al.  The influence of age on the response to anticoagulants. , 1977, British journal of clinical pharmacology.

[25]  T. Moreland,et al.  Age as a determinant of sensitivity to warfarin. , 1977, British journal of clinical pharmacology.

[26]  M. Rawlins,et al.  PREDICTING PATIENTS' WARFARIN REQUIREMENTS , 1977, The Lancet.

[27]  E. Triggs,et al.  WARFARIN SODIUM: STEADY‐STATE PLASMA LEVELS AND PATIENT AGE , 1978, Clinical and experimental pharmacology & physiology.

[28]  J. Suttie,et al.  Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition. , 1978, Biochemistry.

[29]  L. B. Wingard,et al.  Pharmacokinetics of warfarin enantiomers: A search for intrasubject correlations , 1978, Clinical pharmacology and therapeutics.

[30]  M. Rawlins,et al.  Pharmacokinetics and pharmacodynamics of warfarin at steady state. , 1979, British journal of clinical pharmacology.

[31]  P. Meffin,et al.  Effects of clofibrate and warfarin alone and in combination on the disposition of vitamin K1. , 1979, The Journal of pharmacology and experimental therapeutics.

[32]  R. Karl,et al.  A simple technic for predicting daily maintenance dose of warfarin. , 1979, American journal of surgery.

[33]  Clofibrate displaces warfarin from plasma proteins in man: an example of a pure displacement interaction. , 1979, The Journal of pharmacology and experimental therapeutics.

[34]  A. Shepherd,et al.  Warfarin sensitivity in the elderly , 1979 .

[35]  J. Kelly,et al.  Clinical Pharmacokinetics of Oral Anticoagulants , 1979, Clinical pharmacokinetics.

[36]  G Levy,et al.  Effect of naproxen on the steady‐state serum concentration and anticoagulant activity of warfarin , 1979, Clinical pharmacology and therapeutics.

[37]  Predicting warfarin maintenance dosage based on initial response. , 1979, American journal of hospital pharmacy.

[38]  W T Sawyer,et al.  Digital computer-assisted warfarin therapy: comparison of two models. , 1979, Computers and biomedical research, an international journal.

[39]  Adesh K. Jain,et al.  Effect of naproxen on the kinetics of elimination and anticoagulant activity of a single dose of warfarin , 1979, Clinical pharmacology and therapeutics.

[40]  Predictability of warfarin dose requirements: theoretical considerations. , 1979, Journal of pharmaceutical sciences.

[41]  C. Hignite,et al.  Kinetics of R and S warfarin enantiomers , 1980 .

[42]  W. Trager,et al.  Stereoselective interaction of phenylbutazone with [12C/13C]warfarin pseudoracemates in man. , 1980, The Journal of clinical investigation.

[43]  Lewis B. Sheiner,et al.  The NONMEM System , 1980 .

[44]  J. Lian,et al.  Carboxylated calcium-binding proteins and vitamin K. , 1980, The New England journal of medicine.

[45]  David G. Covell,et al.  Systems and Microcomputer Approach to Anticoagulant Therapy , 1980, IEEE Transactions on Biomedical Engineering.

[46]  L. Sheiner,et al.  Understanding the Dose-Effect Relationship , 1981, Clinical pharmacokinetics.

[47]  Predictability of the warfarin maintenance dosage based on the initial response. , 1981, The Journal of the American Osteopathic Association.

[48]  C. Shively,et al.  Antipyrine and warfarin disposition in a patient with idiopathic hypoalbuminemia , 1981, Clinical pharmacology and therapeutics.

[49]  J. Suttie,et al.  Evidence that warfarin anticoagulant action involves two distinct reductase activities. , 1982, The Journal of biological chemistry.

[50]  C. Towler,et al.  Comparison of the bioavailabilities and anticoagulant activities of two warfarin formulations , 1982, British journal of haematology.

[51]  M. Fasco,et al.  R- and S-Warfarin inhibition of vitamin K and vitamin K 2,3-epoxide reductase activities in the rat. , 1982, The Journal of biological chemistry.

[52]  Predicting the dose of warfarin for therapeutic anticoagulation. , 1982, Thrombosis and haemostasis.

[53]  T J O'Leary,et al.  Evaluation of a computer‐assisted method for individualized anticoagulation: Retrospective and prospective studies with a pharmacodynamic model , 1982, Clinical pharmacology and therapeutics.

[54]  G. Raskob,et al.  Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. , 1982, The New England journal of medicine.

[55]  L B Sheiner,et al.  Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. , 1982, Journal of pharmaceutical sciences.

[56]  T B Kirkwood,et al.  Calibration of Reference Thromboplastins and Standardisation of the Prothrombin Time Ratio , 1983, Thrombosis and Haemostasis.

[57]  S Dobrzanski PREDICTING WARFARIN DOSAGE , 1983, Journal of clinical and hospital pharmacy.

[58]  R. Hamilton,et al.  Prediction of Maintenance Warfarin Dosage from Initial Patient Response , 1983, Drug intelligence & clinical pharmacy.

[59]  E. Chan,et al.  Phenylbutazone-warfarin interaction in man: further stereochemical and metabolic considerations. , 1983, British journal of clinical pharmacology.

[60]  Relationships between Steady-State Warfarin Concentrations and Anticoagulant Effect , 1984 .

[61]  Sawyer Wt,et al.  Effect of heparin on prothrombin time. , 1984 .

[62]  S. Gitel,et al.  Warfarin. From bedside to bench. , 1984, The New England journal of medicine.

[63]  The optimal duration of initial heparin treatment for venous thromboembolism , 1984 .

[64]  A. Breckenridge,et al.  Plasma disposition of vitamin K1 in relation to anticoagulant poisoning. , 1984, British journal of clinical pharmacology.

[65]  P. Faraci,et al.  Warfarin Dosage following Prosthetic Valve Replacement: Effect of Smoking History , 1984, Drug intelligence & clinical pharmacy.

[66]  Warfarin maintenance-dose prediction based upon initial anticoagulant response. , 1984 .

[67]  Monitoring effects of oral anticoagulants during treatment with heparin. , 1984, British medical journal.

[68]  D. P. Bentley,et al.  Flexible induction dose regimen for warfarin and prediction of maintenance dose. , 1984, British medical journal.

[69]  D. W. Hawkins,et al.  Plasma protein binding of warfarin: methodological considerations. , 1984, Journal of pharmaceutical sciences.

[70]  USE OF A WARFARIN DOSE PREDICTION METHOD , 1984, Journal of clinical and hospital pharmacy.

[71]  M. Blombäck,et al.  Intensive Initial Oral Anticoagulation and Shorter Heparin Treatment in Deep Vein Thrombosis , 1984, Thrombosis and Haemostasis.

[72]  A model which predicts maintenance warfarin dosage requirements from the response to a single dose. , 1985, British journal of clinical pharmacology.

[73]  S. Lewis,et al.  Reliability and Clinical Impact of the Normalization of the Prothrombin Times in Oral Anticoagulant Control , 1985, Thrombosis and Haemostasis.

[74]  E. Loeliger ICSH/ICTH recommendations for reporting prothrombin time in oral anticoagulant control. , 1985, Haematologica.

[75]  D. Mungall,et al.  Bayesian pharmacokinetic/pharmacodynamic forecasting of prothrombin response to warfarin therapy: preliminary evaluation. , 1985, Therapeutic drug monitoring.

[76]  International Committee for Standardization in Haematology, International Committee on Thrombosis and Haemostasis: ICSH/ICTH recommendations for reporting prothrombin time in oral anticoagulant control. , 1985, Thrombosis and haemostasis.

[77]  D. Kirking,et al.  RELATIONSHIP OF AGE, WEIGHT AND BODY SURFACE AREA TO WARFARIN MAINTENANCE DOSE REQUIREMENTS , 1985, Journal of clinical and hospital pharmacy.

[78]  J. Barré,et al.  Pharmacokinetics of warfarin in the nephrotic syndrome and effect on vitamin K-dependent clotting factors. , 1986, Clinical nephrology.

[79]  A. Breckenridge,et al.  Abnormal vitamin K metabolism in the presence of normal clotting factor activity in factory workers exposed to 4-hydroxycoumarins. , 1986, British journal of clinical pharmacology.

[80]  B. Diquet,et al.  The warfarin-cimetidine interaction: stereochemical considerations. , 1986, British journal of clinical pharmacology.

[81]  W. Stigelman,et al.  Goodman and Gilman's the Pharmacological Basis of Therapeutics , 1986 .